ABSTRACT

Introduction: Community-based voluntary counselling and testing (CBVCT) services for men who have sex with men (MSM) can reach those most-at-risk and provide an environment for gay men that is likely to be non-stigmatising. Longitudinal data on the behaviour of HIV-negative MSM are scarce in Europe. The aim of this protocol, developed during the Euro HIV Early Diagnosis And Treatment (EDAT) project, is to implement a multicentre community-based cohort of HIV-negative MSM attending 15 CBVCT services in 5 European countries.

Research objectives: (1) To describe the patterns of CBVCT use, (2) to estimate HIV incidence, and to identify determinants of (3) HIV seroconversion and (4) HIV and/or sexually transmitted infection (STI) test-seeking behaviour.

Methods and analysis: All MSM aged 18 years or over and who had a negative HIV test result are invited to participate in the COmmunity-BAsed Cohort (COBA-Cohort). Study enrolment started in February 2015, and is due to continue for at least 12 months at each study site. Follow-up frequency depends on the testing recommendations in each country (at least 1 test per year). Sociodemographic data are collected at baseline; baseline and follow-up questionnaires both gather data on attitudes and perceptions, discrimination, HIV/STI testing history, sexual behaviour, condom use, and pre- and post-exposure prophylaxis. Descriptive, exploratory and multivariate analyses will be performed to address the main research objectives of this study, using appropriate statistical tests and models. These analyses will be performed on the whole cohort data and stratified by study site or country.

Ethics and dissemination: The study was approved by the Public Health authorities of each country where the study is being implemented. Findings from the COBA-Cohort study will be summarised in a report to the European Commission, and in leaflets to be distributed to study participants. Articles and conference abstracts will be submitted to peer-reviewed journals and conferences.

INTRODUCTION

In the European Economic Area, the annual rate of HIV diagnoses has remained relatively stable since 2004, with 32 605 new cases reported in 2014 (6.4/100 000 population) when adjusted for reporting delay. In those countries consistently reporting data, the proportion of new infections due to
male-to-male sexual transmission increased from 30% in 2005 to 42% in 2014, while decreasing in all other known transmission groups.\(^1\) In Western Europe, seven countries reported an estimated HIV prevalence in MSM of more than 10% in 2012, ranging from 17.7% in France to 10.2% in Portugal.\(^2\)

Although men who have sex with men (MSM) remain one of the most affected populations for HIV in Europe, direct incidence estimates are scarce because very few cohort studies have been conducted. Those incidence data that are available show that HIV is still spreading rapidly among MSM, with slightly different estimates between countries: 1.2/100 person-years (PYs) in Amsterdam (the Netherlands) in 2014,\(^3\) 3.1/100 PYs in Barcelona (Spain) in 2011\(^4\) and 2.8/100 PYs in Lisbon (Portugal), between 2011 and 2014.\(^5\)

Under the current ‘combination prevention’ paradigm, based on behavioural, biomedical and structural interventions, improving access to and frequency of HIV testing has become one of the main strategies to improve HIV prevention in MSM. Indeed, there is strong evidence of the benefits of early diagnosis and subsequent treatment for individuals (lower mortality and morbidity, higher quality of life, improved life expectancy and overall health) and populations (both behaviour change and antiretroviral therapy reducing onward transmission risk).\(^6\) Although the evidence for reduced sexual risk reduction after HIV testing and counselling in those with a negative test is weaker, a recent study suggested that frequent HIV testing helps HIV-negative MSM to talk more openly about HIV status with their sexual partners, which in turn may reduce serodiscordant condomless anal intercourse.\(^7\)

Frequent voluntary counselling and testing for HIV and other sexually transmitted infections (STIs) in MSM has been recommended for about 10 years.\(^8\)\(^9\) Both WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and WHO and European Centre for Disease Prevention and Control (ECDC) recently reminded that annual HIV/STI testing for sexually active MSM is a minimum, and \(10\)\(^{–}\)\(^11\) Despite these recommendations, the observed proportions of MSM tested within the previous 12 months in the European MSM Internet Survey (EMIS) ranged from 20% in Lithuania to 47% in France,\(^12\)\(^{–}\)\(^13\) suggesting that there is considerable scope to increase frequent HIV testing within combined prevention Public Health strategies.

Barriers to the uptake of HIV (re-)testing are well known and may exist at individual, health provider and institutional levels.\(^6\) MSM face additional, specific barriers to testing, such as homophobia and internalised homonegativity.\(^13\)\(^–\)\(^17\) To help overcome these barriers, many European countries have implemented or at least authorised community-based voluntary counselling and testing (CBVCT) services (as defined in the HIV-COBATEST project: HIV COmmunity-BAsed TESTing practices in Europe\(^18\)) targeting key populations, including MSM. CBVCT services targeting MSM manage to reach those most at risk,\(^19\)\(^–\)\(^21\) probably because peer counselling is well adapted to the culture of MSM, understands their practices, and addresses homophobia and worries of rejection. Several studies have also shown that CBVCT has contributed to increasing testing frequency among MSM\(^19\)\(^–\)\(^20\) and has improved linkage to care.\(^22\)\(^–\)\(^23\)

Conducting longitudinal studies within CBVCT services is challenging because their work is focused on HIV testing and prevention activities, and the systems employed to guarantee anonymity may hinder identification of returning individuals. Although data are routinely collected by CBVCT services to monitor their testing activity, these are often underexploited and report test positivity rates rather than the proportion of users who test positive for HIV.

This study protocol thus proposes to implement a service-based cohort of HIV-negative MSM among attendees of existing CBVCT services targeting MSM, taking into account the experience of two existing cohorts of MSM in CBVCT services.\(^1\)\(^–\)\(^4\)\(^–\)\(^24\) The protocol was developed within the Euro HIV Early Diagnosis And Treatment project (Euro HIV EDAT: https://eurohivedat.eu/), cofunded by the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA, European Commission). Euro HIV EDAT builds on experience and expertise from the HIV-COBATEST project (study reports available at http://cobatest.org) in which a network of European CBVCT services was developed to share experience and improve early diagnosis in key populations such as MSM.

To the best of our knowledge, this study—the COmmunity-BAsed Cohort (COBA-Cohort)—is the first pan-European longitudinal study involving CBVCT services sharing the same data collection tool and recruitment procedures. It is thus a unique occasion to improve the comparability of incidence data between European countries and to disentangle the observed similarities and peculiarities in the determinants of seroconversion between countries.

**METHODS AND ANALYSIS**

**General study design**

This COBA-Cohort is a pan-European prospective and multicentre cohort of HIV-negative MSM attending 1 of the 15 participating CBVCT services, led by five nongovernmental organisations (NGOs): AIDES, AIDS-Fondet, Ath Checkpoint, Checkpoint LX and Legebitra, from France, Denmark, Greece, Portugal and Slovenia, respectively (figure 1). The current protocol was developed, discussed and agreed on by a working group that includes the coordinating centre (Centre for Epidemiological Studies on HIV/STI of Catalonia (CEEISCAT), Barcelona, Spain), at least one representative of the previously mentioned NGOs and three representatives from external academic institutions (Institute of Tropical Medicine Antwerp in Belgium;
the Institute of Public Health of the University of Porto in Portugal and the Slovenian Institute of Public Health).

The main challenge in developing the protocol of the COBA-Cohort study was to harmonise the methodological procedures and tools in order to obtain comparable data, while maintaining the operative autonomy of the participating CBVCT services. This observational service-based cohort does not aim to change any of the usual procedures of the participating sites, for instance HIV testing recommendations or counselling and testing methods. The follow-up frequency of participants hence depends on the participants’ willingness to return for a test.

Objectives

The main research objectives of this service-based study in MSM are (1) to describe the patterns of CBVCT use, (2) to identify determinants of HIV and/or STI test-seeking behaviour (including repeat testing), (3) to estimate the HIV incidence and (4) to identify risk factors for seroconversion.

Furthermore, determinants for sexual risk behaviour and coinfections could also be described.

Feasibility

The existence of two ongoing HIV-negative MSM cohorts in CBVCT services, at BCN Checkpoint in Barcelona1 and CheckpointLX in Lisbon,24 demonstrates the feasibility of running a service-based pan-European cohort, enrolling and following up MSM within established CBVCT services. CheckpointLX, which is also participating in COBA-Cohort, established and runs the MSM Lisbon Cohort and was enrolling around 600 new participants per year until 2014, taking into account a 30% refusal rate.

The first sites of COBA-Cohort started enrolling participants in early 2015, and the total sample included 2313 individuals by 29 February 2016. Other start dates and interim raw data for each CBVCT service are presented in table 1. As the enrolment phase started only a few weeks before this date in several sites, the corresponding samples are still very small.

These raw data show that CheckpointLX is now recruiting many more participants per year than in previous years, and has a stable refusal rate of 30%.

In smaller centres such as Legebitra (Ljubljana, Slovenia), which performed 480 HIV tests in 2014, the refusal rate is much lower (around 11%). Apart from

Figure 1. Community-based voluntary counselling and testing (CBVCT) services participating in the COmmunity-BAsed Cohort (COBA-Cohort).
the personal motivation of the Slovenian CBVCT users to participate in a research study, this refusal rate may be lower than that of CheckpointLX because they can take advantage of the systematic waiting time before the test to fill in the questionnaire. Additionally, peer counselors may have more time per attendee because the annual number of tests is smaller than at the other sites.

### Inclusion criteria and recruitment

Inclusion criteria are as follows: reporting any kind of sex with another man at least once in the 12 months prior to enrolment, being 18 years or older, being a resident or frequent visitor to the CBVCT service catchment area, having a negative HIV test result at enrolment and providing written consent.

All men attending the participating CBVCT services who meet the inclusion criteria during the recruitment period are offered participation in the cohort. Potential participants are given specific information about the COBA-Cohort and the implications of participation (verbal and written explanations) before giving their written informed consent. CBVCT service attendees who meet the inclusion criteria but decline participation are asked to complete a short questionnaire, to be filled in either by the attendee himself or by a counselor during a face-to-face interview (the refusal questionnaire included the following variables: date of the current test, gender, date and country of birth, country of residence, education, occupation, definition of sexual orientation, date of the last HIV test, main reasons for not participating).

The aim is to make the convenience sample as large as possible (expected to be larger than 4000 participants), and as representative as possible of each site (an essential pre-requisite for descriptive and analytic objectives). Within the framework of Euro HIV EDAT, the enrolment phase was due to start in January 2015 and to end in June 2016 at each site (18 months). However, the start of the cohort has been delayed in almost all sites (see Table 1) due to difficulties in preparing the fieldwork (translations, trainings, pilots, etc) and/or in obtaining the ethics approval.

Nevertheless, all participating CBVCTs already expressed their willingness to continue the recruitment after the originally planned deadline. Those sites that started in 2015 will thus recruit for 18 months (same duration as originally planned), and the others will recruit for a total of at least 12 months.

### Follow-up

Recommendations for testing frequency differ between countries and CBVCT services, but they all recommend having at least one test per year, the frequency usually varying according to the risk profile. Enrolled participants are encouraged to be retested according to these recommendations. Proactive follow-up (calls, SMS, emails, etc) has already been implemented in several participating CBVCT services, would also be

---

**Table 1** Interim enrolment data between the start and 29 February 2016 (raw data)

<table>
<thead>
<tr>
<th>NGOs</th>
<th>CBVCT services</th>
<th>Start dates (mm/dd/yyyy)</th>
<th>Eligible men invited to participate n</th>
<th>Participants enrolled n</th>
<th>Users who declined participation* n (%)</th>
<th>Participants who returned at least once† n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CheckpointLX (Portugal)</td>
<td>Lisbon</td>
<td>01/02/2015</td>
<td>1748</td>
<td>1219</td>
<td>529 (30.3)</td>
<td>220 (18.0)</td>
</tr>
<tr>
<td>Legebitra (Slovenia)</td>
<td>Ljubljana</td>
<td>02/09/2015</td>
<td>324</td>
<td>287</td>
<td>37 (11.4)</td>
<td>69 (24.0)</td>
</tr>
<tr>
<td>AIDS-Fondet (Denmark)</td>
<td>Copenhagen</td>
<td>04/13/2015</td>
<td>697</td>
<td>624</td>
<td>73 (10.5)</td>
<td>107 (17.1)</td>
</tr>
<tr>
<td></td>
<td>Aarhus</td>
<td>05/07/2015</td>
<td>66</td>
<td>52</td>
<td>14 (21.2)</td>
<td>18 (34.6)</td>
</tr>
<tr>
<td>AIDS (France)</td>
<td>Paris 12th</td>
<td>01/05/2016</td>
<td>8</td>
<td>8</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Lyon</td>
<td>01/06/2016</td>
<td>16</td>
<td>15</td>
<td>1 (6.3)</td>
<td>1 (6.7)</td>
</tr>
<tr>
<td></td>
<td>Montpellier</td>
<td>01/07/2016</td>
<td>13</td>
<td>12</td>
<td>1 (7.7)</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td></td>
<td>Paris 8th</td>
<td>01/13/2016</td>
<td>7</td>
<td>7</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Marseille South</td>
<td>01/14/2016</td>
<td>20</td>
<td>19</td>
<td>1 (5.0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Marseille North</td>
<td>01/15/2016</td>
<td>5</td>
<td>5</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Lille</td>
<td>01/20/2016</td>
<td>13</td>
<td>12</td>
<td>1 (7.7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Paris 2nd</td>
<td>01/21/2016</td>
<td>6</td>
<td>6</td>
<td>0 (0)</td>
<td>1 (16.7)</td>
</tr>
<tr>
<td></td>
<td>Nice</td>
<td>01/22/2016</td>
<td>32</td>
<td>18</td>
<td>14 (43.8)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Paris 19th</td>
<td>01/27/2016</td>
<td>9</td>
<td>8</td>
<td>1 (11.1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Athens</td>
<td>02/15/2015</td>
<td>33</td>
<td>21</td>
<td>12 (36.4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Total</td>
<td>15 sites</td>
<td>01/02/2015</td>
<td>2997</td>
<td>2313</td>
<td>684 (22.8)</td>
<td>417 (18.0)</td>
</tr>
</tbody>
</table>

*May be under-reported in several sites.
†May include duplicates in several sites.
CBVCT, community-based voluntary counselling and testing; NGO, non-governmental organisation.
offered to all study participants in order to improve repeat testing rates for those accepting reminders.

At each follow-up visit, participants undergo HIV testing and peer counselling, and are offered prevention supplies (condoms, lubricants, brochures, etc) by the CBVCT services. In case of a reactive test during follow-up, participants are offered a confirmation test in accordance with country diagnosis guidelines. In some of the participating CBVCT services, the confirmatory test can be conducted onsite. In others, participants are referred to a laboratory or health facility for confirmatory testing and access to standard public HIV care in their country. Linkage to care procedures in European CBVCT services are being investigated as part of another work package of the Euro HIV EDAT project.

COBA-Cohort participants will be followed up at least until the end of the study period planned in the Euro HIV EDAT project (March 2017). However, all participating CBVCT services are aware of the importance of continuing the follow-up in such a study. Some have already expressed their willingness to continue the follow-up beyond this date.

The study group is currently exploring opportunities to obtain extra funds and/or finding alternative solutions that could reduce the workload linked to participation in the COBA-Cohort. In particular, as data entry is one of the most time-consuming tasks for the participating CBVCT services, the possibility of using new technologies such as online or tablet-based self-administered questionnaires is being investigated to overcome this barrier to long-term participation.

Data collection
A common version of each questionnaire (baseline, follow-up and refusal) has been developed and agreed on by the working group. In all but one CBVCT service, questionnaires are self-administered. Participants have to fill in a sociobehavioural questionnaire at inclusion (baseline questionnaire) and a shorter version (follow-up questionnaire) every time they return to the CBVCT service.

These questionnaires collect data on the sociodemographic profile (baseline questionnaire only), general health and HIV risk, HIV testing (history, patterns, intentions and attitudes), sexual behaviour (history, type of partners, condom use, partner’s serological status data, etc), STIs, and hepatitis B and C (history, testing patterns and vaccines), and pre- and post-exposure prophylaxis (awareness, use and intention to use). Several questions also gathered information about alcohol and drug use during sex (type of drugs and frequency) as well as history of injecting drug use (whether or not related to sex, including the date of the last injection).

In the baseline questionnaire, questions refer to ‘the past 12 months’ and ‘since the last visit’ in the follow-up questionnaire. Indeed, as the frequency of follow-up is not fixed (eg, visiting every 6 months), follow-up questions about participants’ behaviour prior to their visits refer to ‘since the last visit’ in order to cover all the exposure time between two visits. The original questionnaires were developed in English, and then translated by each NGO into their local language(s) before piloting them internally.

During each visit, CBVCT providers also collect data about the general characteristics of each participant’s visit (counselling, type of test, confirmatory testing), biomedical data (test and confirmatory test results, access to the results) and linkage to care (if applicable). These indicators are mainly derived from the standardised form currently used in the European COBATEST network of CBVCT services.

Data management
To facilitate sharing and harmonisation of the data gathered through the self-administered questionnaires, the coordinating centre has implemented a web-based data collection tool (secured by an https connection protocol) enabling CBVCT service providers to enter the paper questionnaires online. Nevertheless, each participating CBVCT service can also use its own data collection approach. Indeed, as CheckpointLX already had its own data collection tool, its use was continued. In France, AIDES developed a tablet-based self-administered questionnaire to be filled in by the enrolled participants themselves because CBVCT service providers are not allowed to enter the participants’ questionnaire data under current French ethical guidelines. Since this latter model of data collection would considerably reduce the time dedicated to COBA-Cohort in each site, the study group aims to generalise it in the coming months.

For the moment, CBVCT services using the paper questionnaires must perform regular data entry of the inclusion, follow-up and refusal questionnaires. This allows the coordinating centre to centralise the data every 6 months in order to monitor the study and perform interim analyses. In the CBVCT services using their own data collection tool, cumulative data sets in a pre-established format are sent to the coordinating centre, to be merged with the rest of the data.

According to local data protection laws and ethical guidelines, personal identifiable information of the participants (name, email address, etc) may be collected locally by the CBVCT service to remind participants to come back for a test, but such data are not entered into the central cohort database managed by the coordinating centre; each participant will only be identified by an anonymous unique participant identifier in the cohort database.

Statistical analysis
The study aims to recruit a convenience sample of CBVCT service users that is as representative as possible, offering participation in the study to all eligible MSM attending the participating CBVCT services during the recruitment period, and collecting basic sociodemographic data for those declining participation.
The sociodemographic profile of MSM declining to participate will be compared with that of those enrolled in the cohort study and should any significant differences be found between both groups, the final sample will be weighted to compensate for selection bias. The estimated weight to be applied will be computed as the inverse of the probability of participation on the basis of the sociodemographic data.

Descriptive analyses will then be performed on each variable in order to describe the activity and the main characteristics of the cohort (for the total cohort and separately for each CBVCT service or NGO).

Other descriptive, exploratory or multivariate analyses will be performed to address the main research objectives of this study (patterns of use of CBVCT; HIV/STI testing behaviour and sexual risk taking). χ² Tests will be used to compare categorical variables, and Student's t-test or Mann-Whitney U test for continuous variables, as appropriate.

The HIV incidence rate (with 95% CI) will be estimated for the total cohort and if sample size allows for each CBVCT service or NGO among participants having at least one follow-up visit. The follow-up time of participants will start at the date of the baseline visit and end at the date of HIV seroconversion or last HIV-negative test. The incidence will thus correspond to the number of HIV seroconversions (ie, a first positive HIV test after a negative HIV test in a previous visit) divided by PYs of follow-up. We will also identify factors associated with HIV seroconversion, using multivariate Cox regression models. HRs and their 95% CIs will be computed.

In longitudinal analyses, differences in the period of time between visits will be taken into account by using the appropriate statistical models (eg, generalised estimating equation and mixed-effects models).

ETHICS AND DISSEMINATION

The coordinating centre and all NGOs except Ath Checkpoint have been involved in the HIV-COBATEST,10 also funded by the European Commission. The coordinating centre and several partners of the present study have also taken part in other European projects such as SIALON11–13 and EMIS.14

The first study results will be published at the end of the Euro HIV EDAT study period (September 2017) in a report for the CHAFEA, European Commission. This report will address all the research objectives of this study, and will be published after approval from the steering committee members and the advisory board of the Euro HIV EDAT project. A brochure based on the main study results will be published and translated into various languages in order to be distributed by the participating CBVCT services to the men who took part in the cohort.

At the end of the recruitment period, a first scientific article describing the COBA-Cohort profile will be published in a peer-reviewed journal, and other articles and conference abstracts will be submitted to international journals and conferences to disseminate the results of specific analyses. Regular brochures for participants will provide an insight into the evolution of the cohort.

APPLICABILITY AND PERSPECTIVES

The implementation of such a cohort of HIV-negative MSM in different European countries, sharing methodology and data, should contribute to improved scientific knowledge of the uptake of community-based testing, HIV and STI testing patterns, and the trends in HIV testing and sexual behaviours over time, and from test to test in this population. It will also be an opportunity to compare the behaviour and attitudes of MSM between countries and in various contexts (including health systems), highlighting the specific characteristics of each local situation.

These data will be crucial to design better preventive interventions aiming at increasing test uptake among MSM. HIV incidence data are also very important measures that will help in identifying the specific subgroups that are even more affected by HIV. Indeed, a recent cohort study showed that it was possible to identify subgroups of MSM with a much higher incidence, even in low-incidence contexts.20 The results will also contribute to increased knowledge of the care cascade in Europe, in particular in those sites where data regarding linkage to care are available.

Some of the main challenges of this pan-European multicentre prospective cohort of HIV-negative MSM are (1) to make it sustainable over time and (2) to include other CBVCT services in order to better reflect the diversity of European MSM. At the time of publication of this article, the study group was already in contact with other European CBVCT services that would be willing to join the study.

Author affiliations

1Centre for Epidemiological Studies on HIV/STI of Catalonia (CEEISCAT), Agència de Salut Pública de Catalunya (ASPC), Generalitat de Catalunya, Badalona, Spain
2The Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain
3CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
4GAT-Grupo de Ativistas em Tratamentos, Lisbon, Portugal
5AIDES (MIRE-Mission Innovation Recherche Expérimentation), Pantin, France
6Groupe de Recherche en Psychologie Sociale (GRePS) EA4163, Université de Lyon 2, Bron, France
7AIDS-Fondet, Copenhagen, Denmark
8Legebitra, Ljubljana, Slovenia
9Ath Checkpoint, Athens, Greece
10EPUnit, Institute of Public Health, University of Porto, Porto, Portugal
11Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Porto, Portugal
12National Institute of Public Health, Ljubljana, Slovenia
13Institute of Tropical Medicine, Antwerp, Belgium
14Department of Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine, Univ Autonoma Barcelona, Badalona, Spain

Acknowledgements The authors would like to thank Michael Meulbroek and Ferran Pujol from BCN Checkpoint (Spain), as well as Michael Wurm,
Christian Gładel and Ralf Dierichs from AIDS-Hilfe NRW e.V. (Essen, Germany), for their input into the preliminary discussions of the project, although for various reasons they were unable to take part in the project.

Collaborators Euro HIV EDAT Study Group, Principal investigator: JC (ICO-CEEISCAT). Main partner: CA. LFL and NL (ICO-CEEISCAT, Spain). Associated partners: Michael Meulbroek, Ferran Pujol and Félix Pérez (Projecte dels NOMS-Hispanosida, Spain); DRC, SM, Sarah Benayoun, Laura Rios and Virginia Laporte (AIDES, France); Klaus Legau, PSK and FP Fondet til bekæmpelse af AIDS (AIDS-Fondet), Denmark); Irena Klavš and Tanja Kustec (National Institute of Public Health, Slovenia); Miha Lobnik and BC (Držuško Kulturno, informacijsko in svetovalno središče Legebitra, Slovenia); Christian Gładel, Michael Wurm, Ralf Dierichs and Oliver Schubert (AIDS-Hilfe NRW e.V., Germany); Galina Musat and Liliana Velica (ARAS—Romanian Association Against AIDS, Romania); Eric Florence and TP (Institute of Tropical Medicine, Belgium); Luis de la Fuente, María José Belza and Sonia Fernández (Instituto de Salud Carlos III (ISCIII), Spain); RF and Daniel Simões (B-Grup de Activistas en Tratamientos, Portugal); SC and Nikos Debes (Positive Voice, Ath Checkpoint). Collaborating partners: Ulrich Marcus (Robert Koch Institute; Germany); Sebastián Meyer (Stop Sida, Spain); Christian Gladel and Ralf Dierichs from AIDS-Hilfe NRW e.V. (Essen, Germany); Rafael Díaz Prieto, Carlos Olaya, Lidia Tovar and Juan Ramón del Palacio (ICO-COBATEST, Spain); RF, LFL and NL (ICO-CEEISCAT, Spain); Hrvoje Fucek (Association of Gay and Lesbian Rights Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Ulrich Marcus (Robert Koch Institute; Germany); Sebastián Meyer (Stop Sida, Spain); Maria José Belza and Sonia Fernández (Instituto de Salud Carlos III (ISCIII), Spain); RF and Daniel Simões (B-Grup de Activistas en Tratamientos, Portugal); SC and Nikos Debes (Positive Voice, Ath Checkpoint). Collaborating partners: Ulrich Marcus (Robert Koch Institute; Germany); Sebastián Meyer (Stop Sida, Spain); Rafael Díaz Prieto, Carlos Olaya, Lidia Tovar and Juan Ramón del Palacio (ICO-COBATEST, Spain); RF, LFL and NL (ICO-CEEISCAT, Spain); Hrvoje Fucek (Association of Gay and Lesbian Rights Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minorities Rights Centre, Croatia); Mercè Meroño (Àmbit Prevenció, Spain); Hrvoje Fucek (Iskorak—Sexual and Gender Minorities Rights Centre, Croatia); RL and Henrique Barros (Sexual and Gender Minority...


COBA-Cohort: a prospective cohort of HIV-negative men who have sex with men, attending community-based HIV testing services in five European countries (a study protocol)

Nicolas Lorente, Laura Fernández-López, Ricardo Fuertes, Daniela Rojas Castro, François Pichon, Bojan Cigan, Sophocles Chanos, Paula Meireles, Raquel Lucas, Stéphane Morel, Per Slaaen Kaye, Cristina Agustí, Irena Klavs, Tom Platteau and Jordi Casabona

BMJ Open 2016 6:
doi: 10.1136/bmjopen-2016-011314

Updated information and services can be found at:
http://bmjopen.bmj.com/content/6/7/e011314

These include:

References
This article cites 15 articles, 4 of which you can access for free at:
http://bmjopen.bmj.com/content/6/7/e011314#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Epidemiology (2176)
- HIV AIDS (187)
- Public health (2287)
- Sexual health (155)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/